JPWO2020031149A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020031149A5 JPWO2020031149A5 JP2021506643A JP2021506643A JPWO2020031149A5 JP WO2020031149 A5 JPWO2020031149 A5 JP WO2020031149A5 JP 2021506643 A JP2021506643 A JP 2021506643A JP 2021506643 A JP2021506643 A JP 2021506643A JP WO2020031149 A5 JPWO2020031149 A5 JP WO2020031149A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- gfral
- tag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 127
- 102100003907 GFRAL Human genes 0.000 claims description 101
- 101700060639 GFRAL Proteins 0.000 claims description 101
- 210000004027 cells Anatomy 0.000 claims description 79
- 102100003273 GDF15 Human genes 0.000 claims description 58
- 101700021530 GDF15 Proteins 0.000 claims description 58
- 102000001253 Protein Kinases Human genes 0.000 claims description 31
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 108091000081 Phosphotransferases Proteins 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 108020004084 membrane receptors Proteins 0.000 claims description 21
- 102000006240 membrane receptors Human genes 0.000 claims description 21
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 claims description 17
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 claims description 17
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 17
- 230000012743 protein tag Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000000051 modifying Effects 0.000 claims description 9
- 102100006051 RET Human genes 0.000 claims description 8
- 101700001630 RET Proteins 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 6
- 230000003247 decreasing Effects 0.000 claims description 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- 108091006822 Human Serum Albumin Proteins 0.000 claims description 4
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 4
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 claims description 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 102000004965 antibodies Human genes 0.000 claims description 4
- 108090001123 antibodies Proteins 0.000 claims description 4
- 230000003899 glycosylation Effects 0.000 claims description 4
- 238000006206 glycosylation reaction Methods 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 108060006633 Protein Kinases Proteins 0.000 description 9
- 230000003834 intracellular Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 8
- 101700034277 JAK1 Proteins 0.000 description 6
- 102100019517 JAK1 Human genes 0.000 description 6
- 102100019516 JAK2 Human genes 0.000 description 6
- 101700016050 JAK2 Proteins 0.000 description 6
- 101700006583 AKT2 Proteins 0.000 description 4
- -1 BAD Proteins 0.000 description 4
- 102100016704 GAB1 Human genes 0.000 description 4
- 102100016695 GAB2 Human genes 0.000 description 4
- 101700083523 GAB2 Proteins 0.000 description 4
- 102100006632 GRB2 Human genes 0.000 description 4
- 101700046691 GRB2 Proteins 0.000 description 4
- 108060006228 PIGU Proteins 0.000 description 4
- 108020004532 RAS Proteins 0.000 description 4
- 102100014742 SHANK3 Human genes 0.000 description 4
- 101710031784 SHANK3 Proteins 0.000 description 4
- 102100016124 SHC1 Human genes 0.000 description 4
- 108010040625 Transforming Protein 1 Src Homology 2 Domain-Containing Proteins 0.000 description 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 3
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 3
- 102100001248 AKT1 Human genes 0.000 description 3
- 101700006234 AKT1 Proteins 0.000 description 3
- 101700074239 GSK3A Proteins 0.000 description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 3
- 108060003497 HAUS7 Proteins 0.000 description 3
- 102100006473 MAP2K1 Human genes 0.000 description 3
- 101710027479 MAP2K1 Proteins 0.000 description 3
- 102100015877 MAP2K2 Human genes 0.000 description 3
- 101710027476 MAP2K2 Proteins 0.000 description 3
- 102100012881 MAP3K11 Human genes 0.000 description 3
- 101710007519 MAP3K11 Proteins 0.000 description 3
- 102100003436 MAP3K5 Human genes 0.000 description 3
- 101700083887 MAPK1 Proteins 0.000 description 3
- 102100016823 MAPK1 Human genes 0.000 description 3
- 101700001448 MAPK3 Proteins 0.000 description 3
- 101710029928 MAPK4 Proteins 0.000 description 3
- 101700028785 MEK1 Proteins 0.000 description 3
- 101700053443 MKK1 Proteins 0.000 description 3
- 102100014833 MKNK1 Human genes 0.000 description 3
- 101700087081 MKNK1 Proteins 0.000 description 3
- 102100014832 MKNK2 Human genes 0.000 description 3
- 101700062305 MKNK2 Proteins 0.000 description 3
- 101700052154 MPK1 Proteins 0.000 description 3
- 102100013322 MTOR Human genes 0.000 description 3
- 108060006638 PDPK1 Proteins 0.000 description 3
- 102100018803 PDPK1 Human genes 0.000 description 3
- 102100016115 RAF1 Human genes 0.000 description 3
- 101700007719 RAF1 Proteins 0.000 description 3
- 101710010021 RPS6KA1 Proteins 0.000 description 3
- 102100012085 RPS6KA1 Human genes 0.000 description 3
- 102100012083 RPS6KA2 Human genes 0.000 description 3
- 101710010020 RPS6KA2 Proteins 0.000 description 3
- 101710009860 RPS6KA3 Proteins 0.000 description 3
- 102100012084 RPS6KA3 Human genes 0.000 description 3
- 102100012082 RPS6KA4 Human genes 0.000 description 3
- 101710009861 RPS6KA4 Proteins 0.000 description 3
- 102100012081 RPS6KA5 Human genes 0.000 description 3
- 101710009858 RPS6KA5 Proteins 0.000 description 3
- 102000001332 SRC Human genes 0.000 description 3
- 101710009384 SRC Proteins 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 101700009925 WNK1 Proteins 0.000 description 3
- 101700069422 ZHX2 Proteins 0.000 description 3
- 101700028563 msk1 Proteins 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000000865 phosphorylative Effects 0.000 description 3
- 101710032514 ACTI Proteins 0.000 description 2
- 102100001250 AKT2 Human genes 0.000 description 2
- 102100006725 AKT3 Human genes 0.000 description 2
- 101700004058 AKT3 Proteins 0.000 description 2
- 102100008372 CBL Human genes 0.000 description 2
- 108050009659 CBL Proteins 0.000 description 2
- 102000004039 Caspase 9 Human genes 0.000 description 2
- 108090000566 Caspase 9 Proteins 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 2
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 2
- 108010093267 Drosophila Son of Sevenless Protein Proteins 0.000 description 2
- 101710019535 FARSA Proteins 0.000 description 2
- 101700083116 FOXO1 Proteins 0.000 description 2
- 101700083961 FOXO3 Proteins 0.000 description 2
- 102100004396 FRS2 Human genes 0.000 description 2
- 101700069831 FRS2 Proteins 0.000 description 2
- 102100018436 GRB10 Human genes 0.000 description 2
- 108010071908 GRB10 Adaptor Protein Proteins 0.000 description 2
- 102100006631 GRB7 Human genes 0.000 description 2
- 108010022046 GRB7 Adaptor Protein Proteins 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102100019155 MDM2 Human genes 0.000 description 2
- 101700032565 MDM2 Proteins 0.000 description 2
- 101710026102 MIC-ACT-2 Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 101700023645 RAC1 Proteins 0.000 description 2
- 101700025113 RAC3 Proteins 0.000 description 2
- 102100001970 RNASE1 Human genes 0.000 description 2
- 101710002310 RNASE1 Proteins 0.000 description 2
- 102100018382 YY1AP1 Human genes 0.000 description 2
- 101710023979 YY1AP1 Proteins 0.000 description 2
- 101710024775 erkB Proteins 0.000 description 2
- 101700024891 EPHB2 Proteins 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
Description
実施形態429.対象は、30以上の肥満度指数を有する、実施形態423~427のいずれか1つの方法。
本発明は以下の態様を含み得る。
[1]
GDF15ペプチドの活性を検出する方法であって、
(i)
(a)細胞表面受容体キナーゼを発現する細胞を提供することと;
(b)前記細胞を前記GDF15ペプチド及び可溶性GFRALと接触させることであって、前記可溶性GFRALは、ドメインD2及びD3を含むGFRAL細胞外ドメインを含む、接触させることと;
(c)前記接触された細胞における生物学的応答を検出することと;又は
(ii)
(a)細胞表面受容体キナーゼ並びにドメインD2及びD3を含むGFRAL細胞外ドメインを発現する細胞を提供することと;
(b)前記細胞を前記GDF15ペプチドと接触させることと;
(c)前記接触された細胞における生物学的応答を検出することと
を含む方法。
[2]
前記GFRAL細胞外ドメインは、ドメインD1を欠く、請求項1に記載の方法。
[3]
細胞表面受容体キナーゼ及びGFRAL細胞外ドメインを発現する細胞を提供し、
(i)前記GFRAL細胞外ドメインは、可溶性GFRAL細胞外ドメインであるか、又は
(ii)前記GFRAL細胞外ドメインは、テザーによって細胞表面に付着される、請求項1又は2に記載の方法。
[4]
前記テザーは、
(i)GFRAL膜貫通ドメイン又はその機能的断片であるか;
(ii)配列番号18のアミノ酸配列又はその機能的変異体を含むか;
(iii)前記GFRAL細胞外ドメインに融合された異種膜貫通ドメインであるか;
(iv)グリコホスファチジルイノシトール(GPI)であるか;
(v)配列番号19のアミノ酸配列若しくはその機能的変異体、配列番号20のアミノ酸配列若しくはその機能的変異体又は配列番号21のアミノ酸配列若しくはその機能的変異体を含むか;
(vi)膜挿入配列であるか;
(vii)配列番号22のアミノ酸配列若しくはその機能的変異体又は配列番号23のアミノ酸配列若しくはその機能的変異体を含むか;又は
(viii)膜挿入脂肪酸である、請求項3に記載の方法。
[5]
前記GFRAL細胞外ドメインは、シグナルペプチドを更に含む、請求項1~4のいずれか一項に記載の方法。
[6]
前記GFRAL細胞外ドメインは、アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化される、請求項1~5のいずれか一項に記載の方法。
[7]
前記GFRAL細胞外ドメインは、
(i)配列番号1のアミノ酸配列又はその機能的変異体を含むか;
(ii)配列番号1のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(iii)配列番号1のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号2のアミノ酸配列又はその機能的変異体を含むか;
(v)配列番号2のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(vi)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(vii)配列番号3のアミノ酸配列又はその機能的変異体を含むか;又は
(viii)配列番号25のアミノ酸配列又はその機能的変異体を含む、請求項1~6のいずれか一項に記載の方法。
[8]
前記GDF15ペプチド又はその機能的変異体は、
(i)配列番号13、14、15、16若しくは17のアミノ酸配列又はその機能的変異体含むか;
(ii)配列番号13のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;又は
(iii)配列番号13のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有する、請求項1~7のいずれか一項に記載の方法。
[9]
前記GDF15ペプチドは、
(i)アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化され;
(ii)ヒト血清アルブミン、マウス血清アルブミン、免疫グロブリン定常領域又はα-1-アンチトリプシンに融合され;
(iii)脂肪酸に抱合され;
(iv)ペグ化を有し;及び/又は
(v)グリコシル化を有する、請求項1~8のいずれか一項に記載の方法。
[10]
前記細胞表面受容体キナーゼは、
(i)内因性細胞表面受容体キナーゼ;
(ii)外因性細胞表面受容体キナーゼ;及び/又は
(iii)RET受容体チロシンキナーゼ
である、請求項1~9のいずれか一項に記載の方法。
[11]
前記細胞は、
(i)内因性GFRAL;
(ii)全長GFRAL;及び/又は
(iii)内因性GDF15
を発現しない、請求項1~10のいずれか一項に記載の方法。
[12]
前記細胞は、無効GDF15遺伝子を含むGDF15ノックアウト(KO)細胞である、請求項1~11のいずれか一項に記載の方法。
[13]
前記生物学的応答は、
(i)前記GDF15ペプチド、前記可溶性GFRAL又は前記GFRAL細胞外ドメイン及び前記細胞表面受容体キナーゼが三元複合体を形成するときに誘導され;
(ii)前記可溶性GFRALの非存在下で前記GDF15ペプチドと接触された細胞において誘導されず;及び/又は
(iii)前記GDF15ペプチド及び/又は前記可溶性GFRALと接触されていない対照細胞内の同じタンパク質の発現又は活性と比較した前記細胞内のタンパク質の発現又は活性の増大又は減少である、請求項1~12のいずれか一項に記載の方法。
[14]
前記生物学的応答は、RET-ERK、RET-AKT、タンパク質キナーゼC、JAK/STAT、JNK、p38及びRAC1経路の1つ以上における細胞内タンパク質の発現又は活性の増大又は減少である、請求項1~13のいずれか一項に記載の方法。
[15]
前記細胞表面受容体キナーゼは、RET受容体チロシンキナーゼであり、及び前記タンパク質は、
(i)ERK1、ERK2、SHC1、FRS2、GRB2、GAB1、GAB2、SOS、SHANK3、GRB7、GRB10、JAK1、JAK2、RAF、RAS、MEK1、MEK2、RSK1、RSK2、RSK3、MNK1、MNK2、MSK1及びMSK2又はその任意の下流標的から選択される、前記RET-ERK経路における細胞内タンパク質であるか;又は
(ii)AKT1、AKT2、AKT3、SRC、SHC1、GRB2、CBL、GAB1、GAB2、SHANK3、JAK1、JAK2、RAS、PI3K、PDK1、YAP、BAD、カスパーゼ-9、FoxO1、FoxO3、FoxO4、IKKα、CREB、MDM2、MLK3、ASK1、p21Cip1、p27Kip1、GSK3α、GSK3β及びmTOR又はその任意の下流標的から選択される、前記RET-AKT経路における細胞内タンパク質である、請求項14に記載の方法。
[16]
前記生物学的応答は、前記GDF15ペプチド及び/又は前記可溶性GFRALと接触されていない対照細胞内の同じタンパク質キナーゼのリン酸化と比較した前記細胞内のタンパク質キナーゼのリン酸化の増大又は減少である、請求項1~15のいずれか一項に記載の方法。
[17]
(i)前記タンパク質キナーゼは、前記細胞表面受容体キナーゼであるか;
(ii)前記タンパク質キナーゼ及び/又は細胞表面受容体キナーゼは、RET受容体チロシンキナーゼであるか;又は
(iii)前記タンパク質キナーゼは、細胞内タンパク質キナーゼであり、前記細胞内タンパク質キナーゼは、前記細胞表面受容体キナーゼによって直接又は間接的にリン酸化される、請求項16に記載の方法。
[18]
前記タンパク質キナーゼは、
(i)ERK1、ERK2、JAK1、JAK2、RAF、MEK1、MEK2、RSK1、RSK2、RSK3、MNK1、MNK2、MSK1及びMSK2又はその任意の下流標的から選択される、前記RET-ERK経路における細胞内タンパク質キナーゼ;又は
(ii)AKT1、AKT2、AKT3、SRC、JAK1、JAK2、PI3K、PDK1、MLK3、ASK1、GSK3α、GSK3β及びmTOR又はその任意の下流標的から選択される、前記RET-AKT経路における細胞内タンパク質キナーゼである、請求項16又は17に記載の方法。
[19]
GDF15ペプチドの活性を検出するための単離及び改変された細胞であって、ドメインD2及びD3を含むGFRAL細胞外ドメイン並びに細胞表面受容体キナーゼを発現する、単離及び改変された細胞。
[20]
前記GFRAL細胞外ドメインは、ドメインD1を欠く、請求項19に記載の細胞。
[21]
前記GFRAL細胞外ドメインは、
(i)可溶性GFRAL細胞外ドメインであるか;又は
(ii)テザーによって細胞表面に付着される、請求項19又は20に記載の細胞。
[22]
前記テザーは、
(i)GFRAL膜貫通ドメイン又はその機能的断片であるか;
(ii)配列番号18のアミノ酸配列又はその機能的変異体を含むか;
(iii)前記GFRAL細胞外ドメインに融合された異種膜貫通ドメインであるか;
(iv)グリコホスファチジルイノシトール(GPI)であるか;
(v)配列番号19のアミノ酸配列若しくはその機能的変異体、配列番号20のアミノ酸配列若しくはその機能的変異体又は配列番号21のアミノ酸配列若しくはその機能的変異体を含むか;
(vi)膜挿入配列であるか;
(vii)配列番号22のアミノ酸配列若しくはその機能的変異体又は配列番号23のアミノ酸配列若しくはその機能的変異体を含むか;又は
(viii)膜挿入脂肪酸である、請求項21に記載の細胞。
[23]
前記GFRAL細胞外ドメインは、シグナルペプチドを更に含む、請求項19~22のいずれか一項に記載の細胞。
[24]
前記GFRAL細胞外ドメインは、アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化される、請求項19~23のいずれか一項に記載の細胞。
[25]
前記GFRAL細胞外ドメインは、
(i)配列番号1のアミノ酸配列又はその機能的変異体を含むか;
(ii)配列番号1のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(iii)配列番号1のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号2のアミノ酸配列又はその機能的変異体を含むか;
(v)配列番号2のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(vi)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(vii)配列番号3のアミノ酸配列又はその機能的変異体を含むか;又は
(viii)配列番号25のアミノ酸配列又はその機能的変異体を含む、請求項19~24のいずれか一項に記載の細胞。
[26]
前記細胞表面受容体キナーゼは、
(i)内因性細胞表面受容体キナーゼ;
(ii)外因性細胞表面受容体キナーゼ;及び/又は
(iii)RET受容体チロシンキナーゼ
である、請求項19~25のいずれか一項に記載の細胞。
[27]
(i)内因性GFRAL;
(ii)全長GFRAL;及び/又は
(iii)内因性GDF15
を発現しない、請求項19~26のいずれか一項に記載の細胞。
[28]
無効GDF15遺伝子を含むGDF15ノックアウト(KO)細胞である、請求項19~27のいずれか一項に記載の細胞。
[29]
哺乳動物細胞、ヒト細胞、MCF7細胞、SH-SY5Y細胞及びHEK293A-GDF15 KO細胞から選択される、請求項19~28のいずれか一項に記載の細胞。
[30]
GDF15ペプチドの活性を検出するためのキットであって、前記GDF15ペプチドと接触するための、請求項19~29のいずれか一項に記載の細胞と;前記接触された細胞における生物学的応答を検出する手段とを含むキット。
[31]
ドメインD2及びD3を含むGFRAL細胞外ドメインを含む可溶性GFRAL。
[32]
前記GFRAL細胞外ドメインは、ドメインD1を欠く、請求項31に記載の可溶性GFRAL。
[33]
前記GFRAL細胞外ドメインは、シグナルペプチドを更に含む、請求項31又は32に記載の可溶性GFRAL。
[34]
前記GFRAL細胞外ドメインは、アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化される、請求項31~33のいずれか一項に記載の可溶性GFRAL。
[35]
前記GFRAL細胞外ドメインは、
(i)配列番号1のアミノ酸配列又はその機能的変異体を含むか;
(ii)配列番号1のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(iii)配列番号1のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号2のアミノ酸配列又はその機能的変異体を含むか;
(v)配列番号2のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(vi)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(vii)配列番号3のアミノ酸配列又はその機能的変異体を含むか;又は
(viii)配列番号25のアミノ酸配列又はその機能的変異体を含む、請求項31~34のいずれか一項に記載の可溶性GFRAL。
[36]
GDF15活性を調節することができる薬剤を同定する方法であって、
(a)請求項19~29のいずれか一項に記載の細胞を前記薬剤及びGDF15ペプチドと接触させることと;
(b)前記接触された細胞における生物学的応答を検出することと
を含み、前記薬剤は、前記接触された細胞における前記生物学的応答が、前記薬剤の非存在下で前記GDF15ペプチドと接触された細胞における前記生物学的応答に対して増大又は減少される場合、GDF15活性を調節すると決定される、方法。
[37]
GDF15活性を調節することができる薬剤を同定する方法であって、
(a)細胞表面受容体キナーゼを発現する細胞を提供することと;
(b)前記細胞をGDF15ペプチド及び可溶性GFRALと接触させることであって、前記可溶性GFRALは、ドメインD2及びD3を含むGFRAL細胞外ドメインを含み、且つドメインD1を欠く、接触させることと;
(c)前記細胞を前記薬剤と接触させることと;
(d)前記接触された細胞における生物学的応答を検出することと
を含み、前記薬剤は、
(i)前記接触された細胞における前記生物学的応答が、前記GDF15ペプチド、前記可溶性GFRAL及び前記薬剤の存在下において、前記薬剤の非存在下で前記GDF15ペプチド及び前記可溶性GFRALと接触された細胞における前記生物学的応答に対して増大される場合、GDF15活性を調節するか又は増大させるか;又は
(ii)前記接触された細胞における前記生物学的応答が、前記GDF15ペプチド、前記可溶性GFRAL及び前記薬剤の存在下において、前記薬剤の非存在下で前記GDF15ペプチド及び前記可溶性GFRALと接触された細胞における前記生物学的応答に対して減少される場合、GDF15活性を調節するか又は減少させると決定される、方法。
[38]
前記GFRAL細胞外ドメインは、アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化される、請求項37に記載の方法。
[39]
前記GFRAL細胞外ドメインは、
(i)配列番号1のアミノ酸配列又はその機能的変異体を含むか;
(ii)配列番号1のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(iii)配列番号1のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号2のアミノ酸配列又はその機能的変異体を含むか;
(v)配列番号2のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;
(vi)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(vii)配列番号3のアミノ酸配列又はその機能的変異体を含むか;又は
(viii)配列番号25のアミノ酸配列又はその機能的変異体を含む、請求項37又は38に記載の方法。
[40]
前記薬剤は、抗GDF15抗体及び抗GFRAL抗体から選択される抗体である、請求項36~39のいずれか一項に記載の方法。
[41]
前記生物学的応答は、RET-ERK、RET-AKT、タンパク質キナーゼC、JAK/STAT、JNK、p38及びRAC1経路の1つ以上における細胞内タンパク質の発現、活性又はリン酸化レベルの増大又は減少である、請求項36~40のいずれか一項に記載の方法。
[42]
前記細胞内タンパク質は、前記RET-ERK経路にあり、且つERK、SHC1、FRS2、GRB2、GAB1、GAB2、SOS、SHANK3、GRB7、GRB10、JAK1、JAK2、RAF、RAS、MEK1、MEK2、RSK1、RSK2、RSK3、MNK1、MNK2、MSK1及びMSK2から選択される、請求項41に記載の方法。
[43]
前記細胞内タンパク質は、前記RET-AKT経路にあり、且つAKT、SRC、SHC1、GRB2、CBL、GAB1、GAB2、SHANK3、JAK1、JAK2、RAS、PI3K、PDK1、YAP、BAD、カスパーゼ-9、FoxO1、FoxO3、FoxO4、IKKα、CREB、MDM2、MLK3、ASK1、p21Cip1、p27Kip1、GSK3α、GSK3β及びmTORから選択される、請求項41に記載の方法。
[44]
前記GDF15ペプチド又はその機能的変異体は、
(i)配列番号13、14、15、16若しくは17のアミノ酸配列又はその機能的変異体含むか;
(ii)配列番号13のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;又は
(iii)配列番号13のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有する、請求項36~43のいずれか一項に記載の方法。
[45]
前記GDF15ペプチドは、
(i)アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化され;
(ii)ヒト血清アルブミン、マウス血清アルブミン、免疫グロブリン定常領域又はα-1-アンチトリプシンに融合され;
(iii)脂肪酸に抱合され;
(iv)ペグ化を有し;及び/又は
(v)グリコシル化を有する、請求項36~44のいずれか一項に記載の方法。
Embodiment 429. The method of any one of embodiments 423-427, wherein the subject has a body mass index of 30 or greater.
The present invention can include the following aspects.
[1]
A method for detecting activity of a GDF15 peptide, comprising:
(i)
(a) providing a cell expressing a cell surface receptor kinase;
(b) contacting said cell with said GDF15 peptide and soluble GFRAL, said soluble GFRAL comprising a GFRAL extracellular domain comprising domains D2 and D3;
(c) detecting a biological response in said contacted cell; or
(ii)
(a) providing a cell expressing a cell surface receptor kinase and a GFRAL extracellular domain comprising domains D2 and D3;
(b) contacting said cell with said GDF15 peptide;
(c) detecting a biological response in said contacted cell;
method including.
[2]
2. The method of claim 1, wherein the GFRAL extracellular domain lacks domain D1.
[3]
providing a cell expressing a cell surface receptor kinase and a GFRAL extracellular domain;
(i) said GFRAL extracellular domain is a soluble GFRAL extracellular domain, or
3. The method of claim 1 or 2, wherein (ii) said GFRAL extracellular domain is attached to the cell surface by a tether.
[4]
The tether is
(i) a GFRAL transmembrane domain or a functional fragment thereof;
(ii) comprises the amino acid sequence of SEQ ID NO: 18 or a functional variant thereof;
(iii) a heterologous transmembrane domain fused to said GFRAL extracellular domain;
(iv) is a glycophosphatidylinositol (GPI);
(v) comprises the amino acid sequence of SEQ ID NO: 19 or a functional variant thereof, the amino acid sequence of SEQ ID NO: 20 or a functional variant thereof, or the amino acid sequence of SEQ ID NO: 21 or a functional variant thereof;
(vi) is a membrane insertion sequence;
(vii) comprises the amino acid sequence of SEQ ID NO:22 or a functional variant thereof or the amino acid sequence of SEQ ID NO:23 or a functional variant thereof; or
(viii) The method according to claim 3, which is a membrane-inserted fatty acid.
[5]
The method of any one of claims 1-4, wherein the GFRAL extracellular domain further comprises a signal peptide.
[6]
6. The method of any one of claims 1-5, wherein the GFRAL extracellular domain is tagged with an affinity tag selected from an amyloid beta precursor protein tag, a histidine tag, a FLAG tag and a myc tag.
[7]
The GFRAL extracellular domain is
(i) comprises the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iii) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iv) comprises the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
(v) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vi) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vii) comprises the amino acid sequence of SEQ ID NO: 3 or a functional variant thereof; or
(viii) The method according to any one of claims 1 to 6, comprising the amino acid sequence of SEQ ID NO:25 or a functional variant thereof.
[8]
The GDF15 peptide or functional variant thereof is
(i) comprises the amino acid sequence of SEQ ID NO: 13, 14, 15, 16 or 17 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 13; or
(iii) having at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:13.
[9]
The GDF15 peptide is
(i) tagged with an affinity tag selected from amyloid beta precursor protein tag, histidine tag, FLAG tag and myc tag;
(ii) fused to human serum albumin, mouse serum albumin, an immunoglobulin constant region or alpha-1-antitrypsin;
(iii) conjugated to a fatty acid;
(iv) has pegylation; and/or
(v) The method of any one of claims 1-8, having glycosylation.
[10]
The cell surface receptor kinase is
(i) an endogenous cell surface receptor kinase;
(ii) an exogenous cell surface receptor kinase; and/or
(iii) RET receptor tyrosine kinase
The method according to any one of claims 1 to 9, wherein
[11]
The cells are
(i) endogenous GFRAL;
(ii) full-length GFRAL; and/or
(iii) endogenous GDF15
The method according to any one of claims 1 to 10, which does not express
[12]
12. The method of any one of claims 1-11, wherein said cells are GDF15 knockout (KO) cells comprising a disabled GDF15 gene.
[13]
The biological response is
(i) induced when said GDF15 peptide, said soluble GFRAL or said GFRAL extracellular domain and said cell surface receptor kinase form a ternary complex;
(ii) not induced in cells contacted with said GDF15 peptide in the absence of said soluble GFRAL; and/or
(iii) an increase or decrease in the expression or activity of a protein in said cell relative to the expression or activity of the same protein in a control cell not contacted with said GDF15 peptide and/or said soluble GFRAL. 13. The method of any one of 12.
[14]
wherein said biological response is an increase or decrease in intracellular protein expression or activity in one or more of the RET-ERK, RET-AKT, protein kinase C, JAK/STAT, JNK, p38 and RAC1 pathways. 14. The method according to any one of 1-13.
[15]
said cell surface receptor kinase is RET receptor tyrosine kinase, and said protein is
(i) ERK1, ERK2, SHC1, FRS2, GRB2, GAB1, GAB2, SOS, SHANK3, GRB7, GRB10, JAK1, JAK2, RAF, RAS, MEK1, MEK2, RSK1, RSK2, RSK3, MNK1, MNK2, MSK1 and MSK2 or an intracellular protein in said RET-ERK pathway, selected from any downstream target thereof; or
(ii) AKT1, AKT2, AKT3, SRC, SHC1, GRB2, CBL, GAB1, GAB2, SHANK3, JAK1, JAK2, RAS, PI3K, PDK1, YAP, BAD, caspase-9, FoxO1, FoxO3, FoxO4, IKKα, CREB , MDM2, MLK3, ASK1, p21Cip1, p27Kip1, GSK3α, GSK3β and mTOR or any downstream target thereof, in the RET-AKT pathway.
[16]
said biological response is an increase or decrease in phosphorylation of a protein kinase in said cell compared to phosphorylation of the same protein kinase in control cells not contacted with said GDF15 peptide and/or said soluble GFRAL; A method according to any one of claims 1-15.
[17]
(i) said protein kinase is said cell surface receptor kinase;
(ii) said protein kinase and/or cell surface receptor kinase is RET receptor tyrosine kinase; or
17. The method of claim 16, wherein (iii) said protein kinase is an intracellular protein kinase, and said intracellular protein kinase is directly or indirectly phosphorylated by said cell surface receptor kinase.
[18]
The protein kinase is
(i) an intracellular protein in said RET-ERK pathway selected from ERK1, ERK2, JAK1, JAK2, RAF, MEK1, MEK2, RSK1, RSK2, RSK3, MNK1, MNK2, MSK1 and MSK2 or any downstream target thereof; kinase; or
(ii) an intracellular protein kinase in the RET-AKT pathway selected from AKT1, AKT2, AKT3, SRC, JAK1, JAK2, PI3K, PDK1, MLK3, ASK1, GSK3α, GSK3β and mTOR or any downstream target thereof; 18. The method of claim 16 or 17, wherein
[19]
An isolated and modified cell for detecting the activity of a GDF15 peptide, said cell expressing a GFRAL extracellular domain comprising domains D2 and D3 and a cell surface receptor kinase.
[20]
20. The cell of claim 19, wherein said GFRAL extracellular domain lacks domain D1.
[21]
The GFRAL extracellular domain is
(i) is a soluble GFRAL extracellular domain; or
21. A cell according to claim 19 or 20, which is (ii) attached to the cell surface by a tether.
[22]
The tether is
(i) a GFRAL transmembrane domain or a functional fragment thereof;
(ii) comprises the amino acid sequence of SEQ ID NO: 18 or a functional variant thereof;
(iii) a heterologous transmembrane domain fused to said GFRAL extracellular domain;
(iv) is a glycophosphatidylinositol (GPI);
(v) comprises the amino acid sequence of SEQ ID NO: 19 or a functional variant thereof, the amino acid sequence of SEQ ID NO: 20 or a functional variant thereof, or the amino acid sequence of SEQ ID NO: 21 or a functional variant thereof;
(vi) is a membrane insertion sequence;
(vii) comprises the amino acid sequence of SEQ ID NO:22 or a functional variant thereof or the amino acid sequence of SEQ ID NO:23 or a functional variant thereof; or
(viii) The cell of claim 21, which is a membrane-inserted fatty acid.
[23]
The cell of any one of claims 19-22, wherein said GFRAL extracellular domain further comprises a signal peptide.
[24]
24. The cell of any one of claims 19-23, wherein said GFRAL extracellular domain is tagged with an affinity tag selected from an amyloid beta precursor protein tag, a histidine tag, a FLAG tag and a myc tag.
[25]
The GFRAL extracellular domain is
(i) comprises the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iii) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iv) comprises the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
(v) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vi) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vii) comprises the amino acid sequence of SEQ ID NO: 3 or a functional variant thereof; or
(viii) The cell according to any one of claims 19-24, comprising the amino acid sequence of SEQ ID NO: 25 or a functional variant thereof.
[26]
The cell surface receptor kinase is
(i) an endogenous cell surface receptor kinase;
(ii) an exogenous cell surface receptor kinase; and/or
(iii) RET receptor tyrosine kinase
The cell according to any one of claims 19 to 25, which is
[27]
(i) endogenous GFRAL;
(ii) full-length GFRAL; and/or
(iii) endogenous GDF15
27. The cell of any one of claims 19-26, which does not express
[28]
28. The cell of any one of claims 19-27, which is a GDF15 knockout (KO) cell comprising a disabled GDF15 gene.
[29]
Cells according to any one of claims 19 to 28, selected from mammalian cells, human cells, MCF7 cells, SH-SY5Y cells and HEK293A-GDF15 KO cells.
[30]
30. A kit for detecting the activity of a GDF15 peptide, comprising a cell according to any one of claims 19 to 29, for contacting with said GDF15 peptide; a means for detecting;
[31]
Soluble GFRAL containing the GFRAL extracellular domain containing domains D2 and D3.
[32]
32. The soluble GFRAL of claim 31, wherein said GFRAL extracellular domain lacks domain D1.
[33]
33. The soluble GFRAL of claim 31 or 32, wherein said GFRAL extracellular domain further comprises a signal peptide.
[34]
Soluble GFRAL according to any one of claims 31 to 33, wherein said GFRAL extracellular domain is tagged with an affinity tag selected from amyloid beta precursor protein tag, histidine tag, FLAG tag and myc tag. .
[35]
The GFRAL extracellular domain is
(i) comprises the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iii) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iv) comprises the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
(v) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vi) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vii) comprises the amino acid sequence of SEQ ID NO: 3 or a functional variant thereof; or
(viii) The soluble GFRAL of any one of claims 31-34, comprising the amino acid sequence of SEQ ID NO: 25 or a functional variant thereof.
[36]
A method of identifying an agent capable of modulating GDF15 activity, comprising:
(a) contacting the cell of any one of claims 19-29 with said agent and a GDF15 peptide;
(b) detecting a biological response in said contacted cell;
wherein the agent increases or decreases the biological response in the contacted cell relative to the biological response in the cell contacted with the GDF15 peptide in the absence of the agent , determined to modulate GDF15 activity.
[37]
A method of identifying an agent capable of modulating GDF15 activity, comprising:
(a) providing a cell expressing a cell surface receptor kinase;
(b) contacting said cell with a GDF15 peptide and soluble GFRAL, said soluble GFRAL comprising GFRAL extracellular domains including domains D2 and D3 and lacking domain D1;
(c) contacting said cell with said agent;
(d) detecting a biological response in said contacted cell;
wherein the agent comprises
(i) said biological response in said contacted cell is in the presence of said GDF15 peptide, said soluble GFRAL and said agent, in the absence of said agent and in cells contacted with said GDF15 peptide and said soluble GFRAL; modulates or increases GDF15 activity if increased to said biological response in; or
(ii) said biological response in said contacted cell is in the presence of said GDF15 peptide, said soluble GFRAL and said agent, in the absence of said agent and in cells contacted with said GDF15 peptide and said soluble GFRAL; determined to modulate or decrease GDF15 activity if it is decreased relative to said biological response in .
[38]
38. The method of claim 37, wherein said GFRAL extracellular domain is tagged with an affinity tag selected from amyloid beta precursor protein tag, histidine tag, FLAG tag and myc tag.
[39]
The GFRAL extracellular domain is
(i) comprises the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iii) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1;
(iv) comprises the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
(v) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vi) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
(vii) comprises the amino acid sequence of SEQ ID NO: 3 or a functional variant thereof; or
(viii) The method of claim 37 or 38, comprising the amino acid sequence of SEQ ID NO: 25 or a functional variant thereof.
[40]
The method of any one of claims 36-39, wherein said agent is an antibody selected from anti-GDF15 and anti-GFRAL antibodies.
[41]
The biological response is an increase or decrease in the expression, activity or phosphorylation level of intracellular proteins in one or more of the RET-ERK, RET-AKT, protein kinase C, JAK/STAT, JNK, p38 and RAC1 pathways. The method of any one of claims 36-40, wherein
[42]
The intracellular proteins are in the RET-ERK pathway and are ERK, SHC1, FRS2, GRB2, GAB1, GAB2, SOS, SHANK3, GRB7, GRB10, JAK1, JAK2, RAF, RAS, MEK1, MEK2, RSK1, RSK2 , RSK3, MNK1, MNK2, MSK1 and MSK2.
[43]
The intracellular proteins are in the RET-AKT pathway and are AKT, SRC, SHC1, GRB2, CBL, GAB1, GAB2, SHANK3, JAK1, JAK2, RAS, PI3K, PDK1, YAP, BAD, caspase-9, FoxO1 , FoxO3, FoxO4, IKKα, CREB, MDM2, MLK3, ASK1, p21Cip1, p27Kip1, GSK3α, GSK3β and mTOR.
[44]
The GDF15 peptide or functional variant thereof is
(i) comprises the amino acid sequence of SEQ ID NO: 13, 14, 15, 16 or 17 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 13; or
(iii) having at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:13.
[45]
The GDF15 peptide is
(i) tagged with an affinity tag selected from amyloid beta precursor protein tag, histidine tag, FLAG tag and myc tag;
(ii) fused to human serum albumin, mouse serum albumin, an immunoglobulin constant region or alpha-1-antitrypsin;
(iii) conjugated to a fatty acid;
(iv) has pegylation; and/or
45. The method of any one of claims 36-44, wherein (v) has glycosylation.
Claims (29)
(i)
(a)RET受容体チロシンキナーゼである細胞表面受容体キナーゼを発現する細胞を提供することと;
(b)前記細胞を前記GDF15ペプチド及び可溶性GFRALと接触させることであって、前記可溶性GFRALは、ドメインD2及びD3からなり、ドメインD1を欠き、配列番号1のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するアミノ酸配列を有するGFRAL細胞外ドメインであって、場合によりシグナルペプチドを更に含むかまたは/およびアミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化されるGFRAL細胞外ドメインを有する、接触させること;および
(c)前記接触された細胞における生物学的応答を検出することと;又は
(ii)
(a)RET受容体チロシンキナーゼである細胞表面受容体キナーゼ並びにGFRAL細胞外ドメインを発現する細胞を提供することであって、前記GFRAL細胞外ドメインは、ドメインD2及びD3からなり、ドメインD1を欠き、配列番号1のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するアミノ酸配列を有するGFRAL細胞外ドメインであって、場合によりシグナルペプチドを更に含むかまたは/およびアミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化される、提供することと;
(b)前記細胞を前記GDF15ペプチドと接触させることと;および
(c)前記接触された細胞における生物学的応答を検出することと
を含む方法。 A method of detecting activity of a GDF15 peptide, comprising:
(i)
(a) providing a cell expressing a cell surface receptor kinase that is the RET receptor tyrosine kinase ;
(b) contacting said cell with said GDF15 peptide and soluble GFRAL, wherein said soluble GFRAL consists of domains D2 and D3 and lacks domain D1 and is at least 90% of the amino acid sequence of SEQ ID NO: 1; GFRAL extracellular domains with identical amino acid sequences, optionally further comprising a signal peptide or/and an affinity tag selected from an amyloid beta precursor protein tag, a histidine tag, a FLAG tag and a myc tag. contacting with a GFRAL extracellular domain tagged ; and
(c) detecting a biological response in said contacted cell; or (ii)
(a) providing a cell expressing a cell surface receptor kinase that is the RET receptor tyrosine kinase and a GFRAL extracellular domain , said GFRAL extracellular domain consisting of domains D2 and D3, comprising domain D1; GFRAL extracellular domain having an amino acid sequence lacking and having at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1, optionally further comprising a signal peptide or/and an amyloid beta precursor protein tag, histidine providing tagged with an affinity tag selected from tag, FLAG tag and myc tag ;
(b) contacting said cell with said GDF15 peptide; and
(c) detecting a biological response in said contacted cell.
(i)前記GFRAL細胞外ドメインは、可溶性GFRAL細胞外ドメインであるか、又は
(ii)前記GFRAL細胞外ドメインは、テザーによって細胞表面に付着される、請求項1に記載の方法。 In (ii) of claim 1 ,
2. The method of claim 1 , wherein (i) the GFRAL ectodomain is a soluble GFRAL ectodomain, or (ii) the GFRAL ectodomain is attached to the cell surface by a tether.
(i)GFRAL膜貫通ドメイン又はその機能的断片であるか;
(ii)配列番号18のアミノ酸配列又はその機能的変異体を含むか;
(iii)前記GFRAL細胞外ドメインに融合された異種膜貫通ドメインであるか;
(iv)グリコホスファチジルイノシトール(GPI)であるか;
(v)配列番号19のアミノ酸配列若しくはその機能的変異体、配列番号20のアミノ酸配列若しくはその機能的変異体又は配列番号21のアミノ酸配列若しくはその機能的変異体を含むか;
(vi)膜挿入配列であるか;
(vii)配列番号22のアミノ酸配列若しくはその機能的変異体又は配列番号23のアミノ酸配列若しくはその機能的変異体を含むか;又は
(viii)膜挿入脂肪酸である、請求項2に記載の方法。 The tether is
(i) a GFRAL transmembrane domain or a functional fragment thereof;
(ii) comprises the amino acid sequence of SEQ ID NO: 18 or a functional variant thereof;
(iii) a heterologous transmembrane domain fused to said GFRAL extracellular domain;
(iv) is a glycophosphatidylinositol (GPI);
(v) comprises the amino acid sequence of SEQ ID NO: 19 or a functional variant thereof, the amino acid sequence of SEQ ID NO: 20 or a functional variant thereof, or the amino acid sequence of SEQ ID NO: 21 or a functional variant thereof;
(vi) is a membrane insertion sequence;
3. The method of claim 2, wherein (vii) comprises the amino acid sequence of SEQ ID NO:22 or a functional variant thereof or SEQ ID NO:23 or a functional variant thereof; or (viii) is a membrane-inserted fatty acid.
(i)配列番号1のアミノ酸配列又はその機能的変異体を有するか;
(ii)配列番号2のアミノ酸配列又はその機能的変異体を有するか;
(iii)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号3のアミノ酸配列又はその機能的変異体を有するか;又は
(v)配列番号25のアミノ酸配列又はその機能的変異体を有する、請求項1~5のいずれか一項に記載の方法。 The GFRAL extracellular domain is
(i) has the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
( ii ) has the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
( iii ) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
( iv ) having the amino acid sequence of SEQ ID NO: 3 or functional variants thereof; or ( v ) having the amino acid sequence of SEQ ID NO: 25 or functional variants thereof. the method of.
(i)配列番号13、14、15、16若しくは17のアミノ酸配列又はその機能的変異体含むか;
(ii)配列番号13のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;又は
(iii)配列番号13のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有する、請求項1~6のいずれか一項に記載の方法。 The GDF15 peptide or functional variant thereof is
(i) comprises the amino acid sequence of SEQ ID NO: 13, 14, 15, 16 or 17 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 13; or (iii) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 13 . A method according to any one of paragraphs.
(i)アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化され;
(ii)ヒト血清アルブミン、マウス血清アルブミン、免疫グロブリン定常領域又はα-1-アンチトリプシンに融合され;
(iii)脂肪酸に抱合され;
(iv)ペグ化を有し;及び/又は
(v)グリコシル化を有する、請求項1~7のいずれか一項に記載の方法。 The GDF15 peptide is
(i) tagged with an affinity tag selected from amyloid beta precursor protein tag, histidine tag, FLAG tag and myc tag;
(ii) fused to human serum albumin, mouse serum albumin, an immunoglobulin constant region or alpha-1-antitrypsin;
(iii) conjugated to a fatty acid;
(iv) having pegylation ; and/or (v) having glycosylation.
(i)内因性GFRAL;
(ii)全長GFRAL;及び/又は
(iii)内因性GDF15
を発現しない、請求項1~8のいずれか一項に記載の方法。 The cells are
(i) endogenous GFRAL;
(ii) full-length GFRAL; and/or (iii) endogenous GDF15
The method according to any one of claims 1 to 8 , which does not express
(i)前記GDF15ペプチド、前記可溶性GFRAL又は前記GFRAL細胞外ドメイン及び前記細胞表面受容体キナーゼが三元複合体を形成するときに誘導され;
(ii)前記可溶性GFRALの非存在下で前記GDF15ペプチドと接触された細胞において誘導されず;及び/又は
(iii)前記GDF15ペプチド及び/又は前記可溶性GFRALと接触されていない対照細胞内の同じタンパク質の発現又は活性と比較した前記細胞内のタンパク質の発現又は活性の増大又は減少である、請求項1~9のいずれか一項に記載の方法。 The biological response is
(i) induced when said GDF15 peptide, said soluble GFRAL or said GFRAL extracellular domain and said cell surface receptor kinase form a ternary complex;
(ii) not induced in cells contacted with said GDF15 peptide in the absence of said soluble GFRAL; and/or (iii) the same protein in control cells not contacted with said GDF15 peptide and/or said soluble GFRAL. 10. The method of any one of claims 1 to 9 , wherein the expression or activity of a protein in said cell is increased or decreased compared to the expression or activity of
(i)可溶性GFRAL細胞外ドメインであるか;又は
(ii)テザーによって細胞表面に付着される、請求項11に記載の細胞。 The GFRAL extracellular domain is
12. The cell of claim 11 , which is (i) a soluble GFRAL extracellular domain; or (ii) attached to the cell surface by a tether.
(i)GFRAL膜貫通ドメイン又はその機能的断片であるか;
(ii)配列番号18のアミノ酸配列又はその機能的変異体を含むか;
(iii)前記GFRAL細胞外ドメインに融合された異種膜貫通ドメインであるか;
(iv)グリコホスファチジルイノシトール(GPI)であるか;
(v)配列番号19のアミノ酸配列若しくはその機能的変異体、配列番号20のアミノ酸配列若しくはその機能的変異体又は配列番号21のアミノ酸配列若しくはその機能的変異体を含むか;
(vi)膜挿入配列であるか;
(vii)配列番号22のアミノ酸配列若しくはその機能的変異体又は配列番号23のアミノ酸配列若しくはその機能的変異体を含むか;又は
(viii)膜挿入脂肪酸である、請求項12に記載の細胞。 The tether is
(i) a GFRAL transmembrane domain or a functional fragment thereof;
(ii) comprises the amino acid sequence of SEQ ID NO: 18 or a functional variant thereof;
(iii) a heterologous transmembrane domain fused to said GFRAL extracellular domain;
(iv) is a glycophosphatidylinositol (GPI);
(v) comprises the amino acid sequence of SEQ ID NO: 19 or a functional variant thereof, the amino acid sequence of SEQ ID NO: 20 or a functional variant thereof, or the amino acid sequence of SEQ ID NO: 21 or a functional variant thereof;
(vi) is a membrane insertion sequence;
13. The cell of claim 12 , wherein (vii) comprises the amino acid sequence of SEQ ID NO: 22 or a functional variant thereof or SEQ ID NO: 23 or a functional variant thereof; or (viii) is a membrane-inserted fatty acid.
(i)配列番号1のアミノ酸配列又はその機能的変異体を有するか;
(ii)配列番号2のアミノ酸配列又はその機能的変異体を有するか;
(iii)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号3のアミノ酸配列又はその機能的変異体を有するか;又は
(v)配列番号25のアミノ酸配列又はその機能的変異体を有する、請求項11~15のいずれか一項に記載の細胞。 The GFRAL extracellular domain is
(i) has the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
( ii ) has the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
( iii ) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
( iv ) having the amino acid sequence of SEQ ID NO: 3 or functional variants thereof; or ( v ) having the amino acid sequence of SEQ ID NO: 25 or functional variants thereof. cells.
(ii)全長GFRAL;及び/又は
(iii)内因性GDF15
を発現しない、請求項11~16のいずれか一項に記載の細胞。 (i) endogenous GFRAL;
(ii) full-length GFRAL; and/or (iii) endogenous GDF15
The cell according to any one of claims 11 to 16 , which does not express
(i)配列番号1のアミノ酸配列又はその機能的変異体を有するか;
(ii)配列番号2のアミノ酸配列又はその機能的変異体を有するか;
(iii)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号3のアミノ酸配列又はその機能的変異体を有するか;又は
(v)配列番号25のアミノ酸配列又はその機能的変異体を有する、請求項19~21のいずれか一項に記載の可溶性GFRAL。 The GFRAL extracellular domain is
(i) has the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
( ii ) has the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
( iii ) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
( iv ) having the amino acid sequence of SEQ ID NO: 3 or functional variants thereof; or ( v ) having the amino acid sequence of SEQ ID NO: 25 or functional variants thereof. of soluble GFRAL.
(a)請求項11~17のいずれか一項に記載の細胞を前記薬剤及びGDF15ペプチドと接触させることと;
(b)前記接触された細胞における生物学的応答を検出することと
を含み、前記薬剤は、前記接触された細胞における前記生物学的応答が、前記薬剤の非存在下で前記GDF15ペプチドと接触された細胞における前記生物学的応答に対して増大又は減少される場合、GDF15活性を調節すると決定される、方法。 A method of identifying an agent capable of modulating GDF15 activity, comprising:
(a) contacting the cell of any one of claims 11-17 with said agent and a GDF15 peptide;
(b) detecting a biological response in said contacted cell, wherein said agent is selected so that said biological response in said contacted cell is in contact with said GDF15 peptide in the absence of said agent; is determined to modulate GDF15 activity when increased or decreased to said biological response in cells affected.
(a)RET受容体チロシンキナーゼである細胞表面受容体キナーゼを発現する細胞を提供することと;
(b)前記細胞をGDF15ペプチド及び可溶性GFRALと接触させることであって、前記可溶性GFRALは、GFRAL細胞外ドメインを有し、前記GFRAL細胞外ドメインは、ドメインD2及びD3からなり、ドメインD1を欠き、配列番号1のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するアミノ酸配列を有するGFRAL細胞外ドメインであって、場合によりシグナルペプチドを更に含むかまたは/およびアミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化される、接触させることと;
(c)前記細胞を前記薬剤と接触させることと;
(d)前記接触された細胞における生物学的応答を検出することと
を含み、前記薬剤は、
(i)前記接触された細胞における前記生物学的応答が、前記GDF15ペプチド、前記可溶性GFRAL及び前記薬剤の存在下において、前記薬剤の非存在下で前記GDF15ペプチド及び前記可溶性GFRALと接触された細胞における前記生物学的応答に対して増大される場合、GDF15活性を調節するか又は増大させるか;又は
(ii)前記接触された細胞における前記生物学的応答が、前記GDF15ペプチド、前記可溶性GFRAL及び前記薬剤の存在下において、前記薬剤の非存在下で前記GDF15ペプチド及び前記可溶性GFRALと接触された細胞における前記生物学的応答に対して減少される場合、GDF15活性を調節するか又は減少させると決定される、方法。 A method of identifying an agent capable of modulating GDF15 activity, comprising:
(a) providing a cell expressing a cell surface receptor kinase that is the RET receptor tyrosine kinase ;
(b) contacting said cell with a GDF15 peptide and soluble GFRAL, said soluble GFRAL having a GFRAL extracellular domain, said GFRAL extracellular domain consisting of domains D2 and D3 and lacking domain D1; a GFRAL extracellular domain having an amino acid sequence having at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 1, optionally further comprising a signal peptide or/and an amyloid beta precursor protein tag, histidine contacting tagged with an affinity tag selected from a tag, a FLAG tag and a myc tag ;
(c) contacting said cell with said agent;
(d) detecting a biological response in said contacted cell, said agent comprising:
(i) said biological response in said contacted cell is in the presence of said GDF15 peptide, said soluble GFRAL and said agent, in the absence of said agent and in cells contacted with said GDF15 peptide and said soluble GFRAL; or (ii) said biological response in said contacted cell is enhanced by said GDF15 peptide, said soluble GFRAL and modulating or decreasing GDF15 activity if in the presence of said agent it is decreased relative to said biological response in cells contacted with said GDF15 peptide and said soluble GFRAL in the absence of said agent Determined, method.
(i)配列番号1のアミノ酸配列又はその機能的変異体を有するか;
(ii)配列番号2のアミノ酸配列又はその機能的変異体を有するか;
(iii)配列番号2のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有するか;
(iv)配列番号3のアミノ酸配列又はその機能的変異体を有するか;又は
(v)配列番号25のアミノ酸配列又はその機能的変異体を有する、請求項24または25に記載の方法。 The GFRAL extracellular domain is
(i) has the amino acid sequence of SEQ ID NO: 1 or a functional variant thereof;
( ii ) has the amino acid sequence of SEQ ID NO: 2 or a functional variant thereof;
( iii ) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO:2;
26. The method of claim 24 or 25 , comprising ( iv ) having the amino acid sequence of SEQ ID NO:3 or a functional variant thereof; or ( v ) having the amino acid sequence of SEQ ID NO:25 or a functional variant thereof.
(i)配列番号13、14、15、16若しくは17のアミノ酸配列又はその機能的変異体含むか;
(ii)配列番号13のアミノ酸配列と少なくとも80%のアミノ酸配列同一性を有するか;又は
(iii)配列番号13のアミノ酸配列と少なくとも90%のアミノ酸配列同一性を有する、請求項23~27のいずれか一項に記載の方法。 The GDF15 peptide or functional variant thereof is
(i) comprises the amino acid sequence of SEQ ID NO: 13, 14, 15, 16 or 17 or a functional variant thereof;
(ii) has at least 80% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 13; or (iii) has at least 90% amino acid sequence identity with the amino acid sequence of SEQ ID NO: 13. A method according to any one of paragraphs.
(i)アミロイドβ前駆体タンパク質タグ、ヒスチジンタグ、FLAGタグ及びmycタグから選択される親和性タグでタグ化され;
(ii)ヒト血清アルブミン、マウス血清アルブミン、免疫グロブリン定常領域又はα-1-アンチトリプシンに融合され;
(iii)脂肪酸に抱合され;
(iv)ペグ化を有し;及び/又は
(v)グリコシル化を有する、請求項23~28のいずれか一項に記載の方法。
The GDF15 peptide is
(i) tagged with an affinity tag selected from amyloid beta precursor protein tag, histidine tag, FLAG tag and myc tag;
(ii) fused to human serum albumin, mouse serum albumin, an immunoglobulin constant region or alpha-1-antitrypsin;
(iii) conjugated to a fatty acid;
(iv) having pegylation; and/or ( v) having glycosylation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862717052P | 2018-08-10 | 2018-08-10 | |
US62/717,052 | 2018-08-10 | ||
PCT/IB2019/056803 WO2020031149A2 (en) | 2018-08-10 | 2019-08-09 | Gfral extracellular domains and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021533743A JP2021533743A (en) | 2021-12-09 |
JPWO2020031149A5 true JPWO2020031149A5 (en) | 2022-08-16 |
Family
ID=68136454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021506643A Withdrawn JP2021533743A (en) | 2018-08-10 | 2019-08-09 | GFRAL extracellular domain and usage |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210340205A1 (en) |
EP (1) | EP3833974A2 (en) |
JP (1) | JP2021533743A (en) |
KR (1) | KR20210044244A (en) |
CN (1) | CN112543869A (en) |
AU (1) | AU2019317813A1 (en) |
CA (1) | CA3106948A1 (en) |
IL (1) | IL280271A (en) |
WO (1) | WO2020031149A2 (en) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2616362T3 (en) | 2002-03-05 | 2017-06-12 | Genentech, Inc. | Novel polypeptides that have sequence similarity with GDNFR and nucleic acids encoding them |
AU2012240102C1 (en) | 2011-04-08 | 2016-09-08 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
JP6254146B2 (en) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | Compositions and methods for treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
WO2014120619A2 (en) | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
BR112016029848A2 (en) | 2014-06-24 | 2017-10-24 | Novo Nordisk As | mic-1 fusion proteins and uses thereof |
ES2883158T3 (en) | 2014-07-30 | 2021-12-07 | Ngm Biopharmaceuticals Inc | Compositions and procedures for use for the treatment of metabolic disorders |
DK3212226T3 (en) | 2014-10-31 | 2020-06-15 | Ngm Biopharmaceuticals Inc | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS |
WO2016102580A1 (en) | 2014-12-22 | 2016-06-30 | Novo Nordisk A/S | Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof |
EP3393494A1 (en) | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
WO2017121865A1 (en) * | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
AU2017228489A1 (en) * | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
WO2017172260A1 (en) * | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
AU2017269496B2 (en) | 2016-05-24 | 2021-03-25 | Novo Nordisk A/S | MIC-1 compounds and use thereof |
CA3038846A1 (en) | 2016-10-12 | 2018-04-19 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
-
2019
- 2019-08-09 CA CA3106948A patent/CA3106948A1/en active Pending
- 2019-08-09 KR KR1020217006778A patent/KR20210044244A/en not_active Application Discontinuation
- 2019-08-09 JP JP2021506643A patent/JP2021533743A/en not_active Withdrawn
- 2019-08-09 AU AU2019317813A patent/AU2019317813A1/en not_active Abandoned
- 2019-08-09 CN CN201980052565.5A patent/CN112543869A/en active Pending
- 2019-08-09 EP EP19782705.8A patent/EP3833974A2/en not_active Withdrawn
- 2019-08-09 US US17/266,828 patent/US20210340205A1/en active Pending
- 2019-08-09 WO PCT/IB2019/056803 patent/WO2020031149A2/en unknown
-
2021
- 2021-01-19 IL IL280271A patent/IL280271A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Asano et al. | Matrix stiffness regulates migration of human lung fibroblasts | |
Walker et al. | In wound repair vimentin mediates the transition of mesenchymal leader cells to a myofibroblast phenotype | |
Okamoto et al. | EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16 | |
Polontchouk et al. | Chronic effects of endothelin‐1 and angiotensin‐II on gap junctions and intercellular communication in cardiac cells | |
Lopes et al. | Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways | |
Zhang et al. | Lateral diffusion of membrane-spanning and glycosylphosphatidylinositol-linked proteins: toward establishing rules governing the lateral mobility of membrane proteins. | |
Ando et al. | Immunological identification of an inward rectifier K+ channel (Kir4. 1) in the intermediate cell (melanocyte) of the cochlear stria vascularis of gerbils and rats | |
Kandror et al. | Comparison of glucose-transporter-containing vesicles from rat fat and muscle tissues: evidence for a unique endosomal compartment | |
Feron et al. | Endothelial nitric oxide synthase targeting to caveolae: specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells | |
Peiró et al. | PC12 cells have caveolae that contain TrkA: caveolae-disrupting drugs inhibit nerve growth factor-induced, but not epidermal growth factor-induced, MAPK phosphorylation | |
US5919576A (en) | Immobilized biological membranes | |
Tarui et al. | Purification and properties of rabbit erythrocyte phosphofructokinase | |
Arvanitis et al. | Two types of detergent‐insoluble, glycosphingolipid/cholesterol‐rich membrane domains from isolated myelin | |
Ormel et al. | VGLUT1 is localized in astrocytic processes in several brain regions | |
CA2279555A1 (en) | Amyloid beta protein (globular assembly and uses thereof) | |
Strohbach et al. | The apelin receptor influences biomechanical and morphological properties of endothelial cells | |
Forest et al. | Optimization of immunostaining on flat-mounted human corneas | |
Zhu et al. | Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells | |
Khan et al. | M1 is a major subtype of muscarinic acetylcholine receptors on mouse colonic epithelial cells | |
Kosobrodova et al. | Cluster of differentiation antibody microarrays on plasma immersion ion implanted polycarbonate | |
JPWO2020031149A5 (en) | ||
Ranzinger et al. | The receptor for advanced glycation end-products (RAGE) plays a key role in the formation of nanotubes (NTs) between peritoneal mesothelial cells and in murine kidneys | |
CN101290321A (en) | Membrane associated protein A2 blood serum detection method, detection reagent kit and its uses | |
Batten et al. | Co-localisation of markers for glycinergic and GABAergic neurones in rat nucleus of the solitary tract: implications for co-transmission | |
RU2021105517A (en) | GFRAL EXTRACELLULAR DOMAIN AND METHODS OF THEIR APPLICATION |